145 related articles for article (PubMed ID: 33665938)
1. Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1.
Daressy F; Malard F; Seguy L; Guérineau V; Apel C; Dumontet V; Robert A; Groo AC; Litaudon M; Bignon J; Desrat S; Malzert-Fréon A; Wiels J; Lescop E; Roussi F
ChemMedChem; 2021 Jun; 16(11):1788-1797. PubMed ID: 33665938
[TBL] [Abstract][Full Text] [Related]
2. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.
Liu L; Liu R; Yang X; Hou X; Fang H
Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497
[TBL] [Abstract][Full Text] [Related]
4. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Optimization of 3-Phenyl-
Li Y; Fan W; Gong Q; Tian J; Zhou M; Li Q; Uwituze LB; Zhang Z; Hong R; Wang R
J Med Chem; 2021 Jul; 64(14):10260-10285. PubMed ID: 34228434
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, stereochemical determination, molecular docking study, in silico pre-ADMET prediction and anti-proliferative activities of indole-pyrimidine derivatives as Mcl-1 inhibitors.
Lamie PF; Philoppes JN
Bioorg Chem; 2021 Nov; 116():105335. PubMed ID: 34509795
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.
Richard DJ; Lena R; Bannister T; Blake N; Pierceall WE; Carlson NE; Keller CE; Koenig M; He Y; Minond D; Mishra J; Cameron M; Spicer T; Hodder P; Cardone MH
Bioorg Med Chem; 2013 Nov; 21(21):6642-9. PubMed ID: 23993674
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Wan Y; Dai N; Tang Z; Fang H
Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
[TBL] [Abstract][Full Text] [Related]
9. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation.
Xu G; Liu T; Zhou Y; Yang X; Fang H
Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors.
Wan Y; Li Y; Yan C; Wen J; Tang Z
Bioorg Chem; 2020 Nov; 104():104217. PubMed ID: 32911192
[TBL] [Abstract][Full Text] [Related]
11. NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
Daressy F; Séguy L; Favre L; Corvaisier S; Apel C; Groo AC; Litaudon M; Dumontet V; Malzert-Fréon A; Desrat S; Roussi F; Robert A; Wiels J
Biomed Pharmacother; 2022 Oct; 154():113546. PubMed ID: 35988426
[TBL] [Abstract][Full Text] [Related]
12. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
Beekman AM; O'Connell MA; Howell LA
ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
[TBL] [Abstract][Full Text] [Related]
13. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
14. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors.
Li R; Cheng C; Balasis ME; Liu Y; Garner TP; Daniel KG; Li J; Qin Y; Gavathiotis E; Sebti SM
Eur J Med Chem; 2015 Jan; 90():315-331. PubMed ID: 25437618
[TBL] [Abstract][Full Text] [Related]
17. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors.
Zhu J; Wang Z; Guo Z; Zhang X; Song T; Guo Y; Ji T; Zhang Z
Arch Pharm (Weinheim); 2020 May; 353(5):e2000005. PubMed ID: 32175625
[TBL] [Abstract][Full Text] [Related]
20. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
Yang C; Chen S; Zhou M; Li Y; Li Y; Zhang Z; Liu Z; Ba Q; Li J; Wang H; Yan X; Ma D; Wang R
ChemMedChem; 2014 Jul; 9(7):1436-52. PubMed ID: 24782462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]